Published in Mol Ther on September 27, 2006
Autophagy in the pathogenesis of disease. Cell (2008) 34.68
Suppression of autophagy in skeletal muscle uncovers the accumulation of ubiquitinated proteins and their potential role in muscle damage in Pompe disease. Hum Mol Genet (2008) 2.15
Autophagy in lysosomal storage disorders. Autophagy (2012) 1.59
Clarifying lysosomal storage diseases. Trends Neurosci (2011) 1.57
Synergy between the pharmacological chaperone 1-deoxygalactonojirimycin and the human recombinant alpha-galactosidase A in cultured fibroblasts from patients with Fabry disease. J Inherit Metab Dis (2011) 1.57
Treating lysosomal storage diseases with pharmacological chaperones: from concept to clinics. EMBO Mol Med (2009) 1.49
Transcription factor EB (TFEB) is a new therapeutic target for Pompe disease. EMBO Mol Med (2013) 1.44
Monitoring autophagy in lysosomal storage disorders. Methods Enzymol (2009) 1.40
Suppression of autophagy permits successful enzyme replacement therapy in a lysosomal storage disorder--murine Pompe disease. Autophagy (2010) 1.38
Glycoengineered acid alpha-glucosidase with improved efficacy at correcting the metabolic aberrations and motor function deficits in a mouse model of Pompe disease. Mol Ther (2009) 1.38
Recessive mutations in EPG5 cause Vici syndrome, a multisystem disorder with defective autophagy. Nat Genet (2012) 1.31
Therapeutic approaches in glycogen storage disease type II/Pompe Disease. Neurotherapeutics (2008) 1.22
Abnormal mannose-6-phosphate receptor trafficking impairs recombinant alpha-glucosidase uptake in Pompe disease fibroblasts. Pathogenetics (2008) 1.20
The pharmacological chaperone N-butyldeoxynojirimycin enhances enzyme replacement therapy in Pompe disease fibroblasts. Mol Ther (2009) 1.17
Why should autophagic flux be assessed? Acta Pharmacol Sin (2013) 1.16
Role of autophagy in the pathogenesis of Pompe disease. Acta Myol (2007) 1.16
Autophagy in cardiovascular biology. J Clin Invest (2015) 1.14
Biochemical and pharmacological characterization of different recombinant acid alpha-glucosidase preparations evaluated for the treatment of Pompe disease. Mol Genet Metab (2008) 1.13
Autophagy and mitochondria in Pompe disease: nothing is so new as what has long been forgotten. Am J Med Genet C Semin Med Genet (2012) 1.10
Skeletal muscle, autophagy, and physical activity: the ménage à trois of metabolic regulation in health and disease. J Mol Med (Berl) (2013) 1.07
Autophagy in skeletal muscle: implications for Pompe disease. Int J Clin Pharmacol Ther (2009) 1.06
Pompe disease: from pathophysiology to therapy and back again. Front Aging Neurosci (2014) 1.06
Fiber type conversion by PGC-1α activates lysosomal and autophagosomal biogenesis in both unaffected and Pompe skeletal muscle. PLoS One (2010) 1.03
When more is less: excess and deficiency of autophagy coexist in skeletal muscle in Pompe disease. Autophagy (2009) 0.99
Long-term observational, non-randomized study of enzyme replacement therapy in late-onset glycogenosis type II. J Inherit Metab Dis (2010) 0.95
Differences in the predominance of lysosomal and autophagic pathologies between infants and adults with Pompe disease: implications for therapy. Mol Genet Metab (2010) 0.93
Murine muscle cell models for Pompe disease and their use in studying therapeutic approaches. Mol Genet Metab (2009) 0.92
Immunomodulatory gene therapy in lysosomal storage disorders. Curr Gene Ther (2009) 0.92
Pharmacological enhancement of α-glucosidase by the allosteric chaperone N-acetylcysteine. Mol Ther (2012) 0.89
The value of muscle biopsies in Pompe disease: identifying lipofuscin inclusions in juvenile- and adult-onset patients. Acta Neuropathol Commun (2014) 0.87
Defects in calcium homeostasis and mitochondria can be reversed in Pompe disease. Autophagy (2015) 0.87
Changes in skeletal muscle qualities during enzyme replacement therapy in late-onset type II glycogenosis: temporal and spatial pattern of mass vs. strength response. J Inherit Metab Dis (2010) 0.85
Exercise ameliorates the detrimental effect of chloroquine on skeletal muscles in mice via restoring autophagy flux. Acta Pharmacol Sin (2013) 0.85
Dysregulation of multiple facets of glycogen metabolism in a murine model of Pompe disease. PLoS One (2013) 0.84
Impaired clearance of accumulated lysosomal glycogen in advanced Pompe disease despite high-level vector-mediated transgene expression. J Gene Med (2009) 0.83
Adult onset glycogen storage disease type II (adult onset Pompe disease): report and magnetic resonance images of two cases. Skeletal Radiol (2009) 0.82
Long-term follow-up results in enzyme replacement therapy for Pompe disease: a case report. J Inherit Metab Dis (2010) 0.79
Effect of enzyme replacement therapy in late onset Pompe disease: open pilot study of 48 weeks follow-up. Neurol Sci (2014) 0.79
Induced pluripotent stem cell technology for disease modeling and drug screening with emphasis on lysosomal storage diseases. Stem Cell Res Ther (2012) 0.79
Autophagy mediated CoCrMo particle-induced peri-implant osteolysis by promoting osteoblast apoptosis. Autophagy (2015) 0.79
Suppression of mTORC1 activation in acid-α-glucosidase-deficient cells and mice is ameliorated by leucine supplementation. Am J Physiol Regul Integr Comp Physiol (2014) 0.78
Therapeutic advances in the management of Pompe disease and other metabolic myopathies. Ther Adv Neurol Disord (2013) 0.78
Assessment of the effect of laser irradiations at different wavelengths (660, 810, 980, and 1064 nm) on autophagy in a rat model of mucositis. Lasers Med Sci (2015) 0.76
"Get the Balance Right": Pathological Significance of Autophagy Perturbation in Neuromuscular Disorders. J Neuromuscul Dis (2016) 0.76
Duvoglustat HCl Increases Systemic and Tissue Exposure of Active Acid α-Glucosidase in Pompe Patients Co-administered with Alglucosidase α. Mol Ther (2017) 0.75
WITHDRAWN: Clearance of lysosomal glycogen accumulation by Transcription factor EB (TFEB) in muscle cells from lysosomal alpha-glucosidase deficient mice. Biochem Biophys Res Commun (2013) 0.75
The influence of a polymorphism in the gene encoding angiotensin converting enzyme (ACE) on treatment outcomes in late-onset Pompe patients receiving alglucosidase alfa. Mol Genet Metab Rep (2016) 0.75
Lysosomal Storage Diseases-Regulating Neurodegeneration. J Exp Neurosci (2016) 0.75
Spinal fusion as a viable treatment option for scoliosis management in Pompe disease: a postoperative 3-year follow-up. Eur Spine J (2015) 0.75
In vivo analysis of autophagy in response to nutrient starvation using transgenic mice expressing a fluorescent autophagosome marker. Mol Biol Cell (2003) 17.55
Autophagy as a regulated pathway of cellular degradation. Science (2000) 17.27
The biogenesis of lysosomes. Annu Rev Cell Biol (1989) 10.73
Autophagy: molecular machinery for self-eating. Cell Death Differ (2005) 8.46
Structure and function of the mannose 6-phosphate/insulinlike growth factor II receptors. Annu Rev Biochem (1992) 5.64
Mannose 6-phosphate receptors: new twists in the tale. Nat Rev Mol Cell Biol (2003) 4.72
Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial. Genet Med (2001) 3.60
Culturing satellite cells from living single muscle fiber explants. In Vitro Cell Dev Biol Anim (1995) 3.54
A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. J Pediatr (2006) 3.45
Autophagy: a regulated bulk degradation process inside cells. Biochem Biophys Res Commun (2004) 3.39
The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature. Pediatrics (2003) 3.24
Lipofuscin: mechanisms of age-related accumulation and influence on cell function. Free Radic Biol Med (2002) 3.09
Relationship between muscle fiber types and sizes and muscle architectural properties in the mouse hindlimb. J Morphol (1994) 2.99
Oxidative stress and autophagy. Antioxid Redox Signal (2006) 2.79
Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk. Pediatrics (2004) 2.33
Clinical manifestation and natural course of late-onset Pompe's disease in 54 Dutch patients. Brain (2005) 2.25
Targeted disruption of the acid alpha-glucosidase gene in mice causes an illness with critical features of both infantile and adult human glycogen storage disease type II. J Biol Chem (1998) 2.24
Enzyme replacement therapy in the mouse model of Pompe disease. Mol Genet Metab (2003) 2.17
Dysfunction of endocytic and autophagic pathways in a lysosomal storage disease. Ann Neurol (2006) 1.92
Photo-oxidative disruption of lysosomal membranes causes apoptosis of cultured human fibroblasts. Free Radic Biol Med (1997) 1.81
Lipofuscin. Int J Biochem Cell Biol (2004) 1.75
Oxidative stress, accumulation of biological 'garbage', and aging. Antioxid Redox Signal (2006) 1.74
Safety and efficacy of recombinant acid alpha-glucosidase (rhGAA) in patients with classical infantile Pompe disease: results of a phase II clinical trial. Neuromuscul Disord (2004) 1.64
Replacing acid alpha-glucosidase in Pompe disease: recombinant and transgenic enzymes are equipotent, but neither completely clears glycogen from type II muscle fibers. Mol Ther (2005) 1.59
Enzyme replacement therapy in late-onset Pompe's disease: a three-year follow-up. Ann Neurol (2004) 1.58
Disease severity in children and adults with Pompe disease related to age and disease duration. Neurology (2005) 1.35
Structural and functional changes of lysosomal acid alpha-glucosidase during intracellular transport and maturation. J Biol Chem (1993) 1.32
Morphological changes in muscle tissue of patients with infantile Pompe's disease receiving enzyme replacement therapy. Muscle Nerve (2003) 1.32
Lysosomal acid alpha-glucosidase consists of four different peptides processed from a single chain precursor. J Biol Chem (2004) 1.31
Human lysosomal alpha-glucosidase. Characterization of the catalytic site. J Biol Chem (1991) 1.15
Generalized glycogen storage and cardiomegaly in a knockout mouse model of Pompe disease. Hum Mol Genet (1998) 1.14
Expression of the insulin-like growth factor-II/mannose-6-phosphate receptor in multiple human tissues during fetal life and early infancy. J Clin Endocrinol Metab (1992) 1.12
Induction of tolerance to a recombinant human enzyme, acid alpha-glucosidase, in enzyme deficient knockout mice. Transgenic Res (2003) 1.03
Uptake and stability of human and bovine acid alpha-glucosidase in cultured fibroblasts and skeletal muscle cells from glycogenosis type II patients. Exp Cell Res (1984) 0.92
Endocytosis in skeletal muscle fibers. Exp Cell Res (1999) 0.91
Age-related morphological changes in skeletal muscle cells of acid alpha-glucosidase knockout mice. Muscle Nerve (2006) 0.89
Enzyme replacement therapy for lysosomal storage disorders: successful transition from concept to clinical practice. Mo Med (2004) 0.86
Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy (2007) 20.92
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Targeted disruption of pyrin, the FMF protein, causes heightened sensitivity to endotoxin and a defect in macrophage apoptosis. Mol Cell (2003) 2.55
Suppression of autophagy in skeletal muscle uncovers the accumulation of ubiquitinated proteins and their potential role in muscle damage in Pompe disease. Hum Mol Genet (2008) 2.15
Dysfunction of endocytic and autophagic pathways in a lysosomal storage disease. Ann Neurol (2006) 1.92
Role of Grb2 in EGF-stimulated EGFR internalization. J Cell Sci (2002) 1.82
Histidyl-tRNA synthetase and asparaginyl-tRNA synthetase, autoantigens in myositis, activate chemokine receptors on T lymphocytes and immature dendritic cells. J Exp Med (2002) 1.78
Activation of the endoplasmic reticulum stress response in autoimmune myositis: potential role in muscle fiber damage and dysfunction. Arthritis Rheum (2005) 1.67
Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathies. Arthritis Care Res (Hoboken) (2010) 1.65
Dysferlin deficiency enhances monocyte phagocytosis: a model for the inflammatory onset of limb-girdle muscular dystrophy 2B. Am J Pathol (2008) 1.65
Reorganization of microtubule nucleation during muscle differentiation. Cell Motil Cytoskeleton (2005) 1.61
Deconstructing Pompe disease by analyzing single muscle fibers: to see a world in a grain of sand... Autophagy (2007) 1.60
Autophagy in lysosomal storage disorders. Autophagy (2012) 1.59
Replacing acid alpha-glucosidase in Pompe disease: recombinant and transgenic enzymes are equipotent, but neither completely clears glycogen from type II muscle fibers. Mol Ther (2005) 1.59
The nutrient-responsive transcription factor TFE3 promotes autophagy, lysosomal biogenesis, and clearance of cellular debris. Sci Signal (2014) 1.58
Autophagy and lysosomes in Pompe disease. Autophagy (2006) 1.54
Molecular editing of cellular responses by the high-affinity receptor for IgE. Science (2014) 1.53
Phosphofructokinase deficiency; past, present and future. Curr Mol Med (2002) 1.52
Transcription factor EB (TFEB) is a new therapeutic target for Pompe disease. EMBO Mol Med (2013) 1.44
Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies: distinct HLA-A, -B, -Cw, -DRB1, and -DQA1 allelic profiles distinguish European American patients with different myositis autoantibodies. Medicine (Baltimore) (2006) 1.39
Suppression of autophagy permits successful enzyme replacement therapy in a lysosomal storage disorder--murine Pompe disease. Autophagy (2010) 1.38
Glycoengineered acid alpha-glucosidase with improved efficacy at correcting the metabolic aberrations and motor function deficits in a mouse model of Pompe disease. Mol Ther (2009) 1.38
Dystrophin is a microtubule-associated protein. J Cell Biol (2009) 1.38
Structural and functional roles of desmin in mouse skeletal muscle during passive deformation. Biophys J (2004) 1.31
Carbohydrate-remodelled acid alpha-glucosidase with higher affinity for the cation-independent mannose 6-phosphate receptor demonstrates improved delivery to muscles of Pompe mice. Biochem J (2005) 1.24
Therapeutic approaches in glycogen storage disease type II/Pompe Disease. Neurotherapeutics (2008) 1.22
Glycogen stored in skeletal but not in cardiac muscle in acid alpha-glucosidase mutant (Pompe) mice is highly resistant to transgene-encoded human enzyme. Mol Ther (2002) 1.19
Temporal neuropathologic and behavioral phenotype of 6neo/6neo Pompe disease mice. J Neuropathol Exp Neurol (2008) 1.19
Microtubules that form the stationary lattice of muscle fibers are dynamic and nucleated at Golgi elements. J Cell Biol (2013) 1.18
Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies: distinct HLA-A, -B, -Cw, -DRB1 and -DQA1 allelic profiles and motifs define clinicopathologic groups in caucasians. Medicine (Baltimore) (2005) 1.18
Microtubule plus-end binding protein EB1 is necessary for muscle cell differentiation, elongation and fusion. J Cell Sci (2009) 1.17
Acid alpha-glucosidase deficiency (Pompe disease). Curr Neurol Neurosci Rep (2007) 1.17
Novel conformation of histidyl-transfer RNA synthetase in the lung: the target tissue in Jo-1 autoantibody-associated myositis. Arthritis Rheum (2007) 1.17
Inhibition of glycogen biosynthesis via mTORC1 suppression as an adjunct therapy for Pompe disease. Mol Genet Metab (2010) 1.17
Increased apoptotic chondrocytes in articular cartilage from adult heterozygous SirT1 mice. Ann Rheum Dis (2012) 1.14
Correction of the enzymatic and functional deficits in a model of Pompe disease using adeno-associated virus vectors. Mol Ther (2002) 1.11
Autophagy and mitochondria in Pompe disease: nothing is so new as what has long been forgotten. Am J Med Genet C Semin Med Genet (2012) 1.10
Kinetics, safety and tolerability of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate in healthy adult subjects. Regul Toxicol Pharmacol (2012) 1.10
Who needs microtubules? Myogenic reorganization of MTOC, Golgi complex and ER exit sites persists despite lack of normal microtubule tracks. PLoS One (2011) 1.05
Review of the regulation and safety assessment of food substances in various countries and jurisdictions. Food Addit Contam Part A Chem Anal Control Expo Risk Assess (2013) 1.05
Induction of tolerance to a recombinant human enzyme, acid alpha-glucosidase, in enzyme deficient knockout mice. Transgenic Res (2003) 1.03
Fiber type conversion by PGC-1α activates lysosomal and autophagosomal biogenesis in both unaffected and Pompe skeletal muscle. PLoS One (2010) 1.03
Mechanisms for sweetness. J Nutr (2012) 0.99
Conjugation of mannose 6-phosphate-containing oligosaccharides to acid alpha-glucosidase improves the clearance of glycogen in pompe mice. J Biol Chem (2004) 0.99
When more is less: excess and deficiency of autophagy coexist in skeletal muscle in Pompe disease. Autophagy (2009) 0.99
Adult inflammatory myopathies. Best Pract Res Clin Rheumatol (2004) 0.98
Relationship between glycogen accumulation and the laforin dual specificity phosphatase. Biochem Biophys Res Commun (2006) 0.97
Diagnostic criteria for polymyositis and dermatomyositis. Lancet (2003) 0.97
Restoration of muscle functionality by genetic suppression of glycogen synthesis in a murine model of Pompe disease. Hum Mol Genet (2009) 0.97
Oral 28-day and developmental toxicity studies of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate. Regul Toxicol Pharmacol (2012) 0.96
Modulation of glycogen synthesis by RNA interference: towards a new therapeutic approach for glycogenosis type II. Hum Mol Genet (2008) 0.95
Differences in the predominance of lysosomal and autophagic pathologies between infants and adults with Pompe disease: implications for therapy. Mol Genet Metab (2010) 0.93
Endothelial cell activation and neovascularization are prominent in dermatomyositis. J Autoimmune Dis (2006) 0.93
Murine muscle cell models for Pompe disease and their use in studying therapeutic approaches. Mol Genet Metab (2009) 0.92
Gene gun bombardment-mediated expression and translocation of EGFP-tagged GLUT4 in skeletal muscle fibres in vivo. Pflugers Arch (2002) 0.91
Pompe disease in a Brazilian series: clinical and molecular analyses with identification of nine new mutations. J Neurol (2009) 0.91
Seasonal influence on the onset of idiopathic inflammatory myopathies in serologically defined groups. Arthritis Rheum (2005) 0.90
Animal models of myositis. Rheum Dis Clin North Am (2002) 0.89
Quantitative evaluation of skeletal muscle defects in second harmonic generation images. J Biomed Opt (2013) 0.89
Skeletal muscle pathology of infantile Pompe disease during long-term enzyme replacement therapy. Orphanet J Rare Dis (2013) 0.88
The value of muscle biopsies in Pompe disease: identifying lipofuscin inclusions in juvenile- and adult-onset patients. Acta Neuropathol Commun (2014) 0.87
Hes-1, a known transcriptional repressor, acts as a transcriptional activator for the human acid alpha-glucosidase gene in human fibroblast cells. Biochem Biophys Res Commun (2002) 0.87
The role of TRAIL in mediating autophagy in myositis skeletal muscle: a potential nonimmune mechanism of muscle damage. Arthritis Rheum (2011) 0.87
Defects in calcium homeostasis and mitochondria can be reversed in Pompe disease. Autophagy (2015) 0.87
Acute, subchronic and genotoxicity studies conducted with Oligonol, an oligomerized polyphenol formulated from lychee and green tea extracts. Food Chem Toxicol (2008) 0.86
Retrograde jejunoduodenal intussusception caused by a migrated percutaneous endoscopic gastrostomy tube. Dig Dis Sci (2005) 0.86
Myositis: an update on pathogenesis. Curr Opin Rheumatol (2004) 0.85
Differences in neuromuscular junctions of laryngeal and limb muscles in rats. Laryngoscope (2012) 0.84
What else is in store for autophagy? Exocytosis of autolysosomes as a mechanism of TFEB-mediated cellular clearance in Pompe disease. Autophagy (2013) 0.84
Impaired organization and function of myofilaments in single muscle fibers from a mouse model of Pompe disease. J Appl Physiol (1985) (2010) 0.84
Genotoxicity and subchronic toxicity studies of DHA-rich oil in rats. Regul Toxicol Pharmacol (2007) 0.83
The values and limits of an in vitro model of Pompe disease: the best laid schemes o' mice an' men... Autophagy (2009) 0.81
Evaluation of the in vitro and in vivo genotoxicity of magnolia bark extract. Regul Toxicol Pharmacol (2007) 0.81